AR096526A1 - Agentes citotóxicos para el tratamiento del cáncer - Google Patents
Agentes citotóxicos para el tratamiento del cáncerInfo
- Publication number
- AR096526A1 AR096526A1 ARP140102188A ARP140102188A AR096526A1 AR 096526 A1 AR096526 A1 AR 096526A1 AR P140102188 A ARP140102188 A AR P140102188A AR P140102188 A ARP140102188 A AR P140102188A AR 096526 A1 AR096526 A1 AR 096526A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- therapeutically effective
- composition according
- effective substance
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Método para tratar el cáncer cerebral que comprende administrar una sustancia terapéuticamente eficaz a un paciente, donde la sustancia terapéuticamente eficaz comprende un compuesto de fórmula (1), o una sal farmacéuticamente aceptable de la misma, donde X es una porción que puede escindirse hidrolítica o enzimáticamente en el cuerpo del paciente de manera dependiente del pH. Reivindicación 19: Una composición farmacéutica para utilizar en el tratamiento del cáncer cerebral caracterizada porque comprende a sustancia terapéuticamente eficaz, donde la sustancia terapéuticamente eficaz comprende un compuesto de fórmula (1) o una sal farmacéuticamente aceptable de la misma, donde X es una porción que puede escindirse hidrolítica o enzimáticamente en el cuerpo del paciente de manera dependiente del pH. Reivindicación 21: La composición farmacéutica de acuerdo con la reivindicación 20, caracterizada porque el agente citotóxico es una antraciclina. Reivindicación 22: La composición farmacéutica de acuerdo con la reivindicación 21, caracterizada porque la antraciclina se selecciona del un grupo formado por doxorubicina, daunorubicina, epirubicina, idarubicina, valrubicina, pirarubicina, zorubicina, aclarubicina, caminomicina, mitoxantrona y ametantrona, o un derivado de cualquiera de los mencionados o una sal farmacéuticamente aceptable de cualquiera de los mencionados. Reivindicación 24: La composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 19 - 23, caracterizada porque el grupo de unión covalente a la proteína se selecciona del grupo formado por maleimida, haloacetamida, haloacetato, piririltio, éster de N-hidroxisuccinimida, isotiocianato, disulfuro, vinilcarbonilo, aziridina y acetileno. Reivindicación 26: La composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 19 - 25, caracterizada porque el ligante comprende un residuo molecular orgánico que contiene, al menos, una cadena de carbono alifático que tiene 1 - 12 átomos de carbono, algunos de los cuales pueden reemplazarse con heteroátomos, o una porción aromática. Reivindicación 28: La composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 19 - 27, caracterizada porque el agente citotóxico y el ligante están unidos por una porción de hidrazona. Reivindicación 29: La composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 19 - 28, caracterizada porque la sustancia terapéuticamente eficaz tiene la estructura de fórmula (2). Reivindicación 35: La composición farmacéutica de acuerdo con la reivindicación 19, caracterizada porque la sustancia terapéuticamente eficaz se administra en combinación con un agente anti-cáncer. Reivindicación 55: Un kit que comprende a sustancia terapéuticamente eficaz para utilizar en el tratamiento del cáncer cerebral, caracterizado porque la sustancia terapéuticamente eficaz comprende un compuesto de fórmula (1), o una sal farmacéuticamente aceptable de la misma, caracterizado porque X es una porción que puede escindirse hidrolítica o enzimáticamente en el cuerpo del paciente de manera dependiente del pH.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361831219P | 2013-06-05 | 2013-06-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR096526A1 true AR096526A1 (es) | 2016-01-13 |
Family
ID=52008558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140102188A AR096526A1 (es) | 2013-06-05 | 2014-06-05 | Agentes citotóxicos para el tratamiento del cáncer |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10278981B2 (es) |
| EP (1) | EP3003489B1 (es) |
| JP (1) | JP2016521705A (es) |
| KR (3) | KR102257647B1 (es) |
| CN (2) | CN105307724A (es) |
| AR (1) | AR096526A1 (es) |
| AU (1) | AU2014274940B2 (es) |
| BR (1) | BR112015030623A2 (es) |
| CA (1) | CA2912908C (es) |
| NZ (1) | NZ631022A (es) |
| TW (1) | TW201446251A (es) |
| WO (1) | WO2014197569A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014274940B2 (en) | 2013-06-05 | 2019-05-23 | Cytrx Corporation | Cytotoxic agents for the treatment of cancer |
| KR102211461B1 (ko) | 2015-08-25 | 2021-02-03 | 난토믹스, 엘엘씨 | 고-정확도 변이 판정을 위한 시스템들 및 방법들 |
| EP3668538A4 (en) * | 2017-08-15 | 2021-06-16 | NantCell, Inc. | HANK-CETUXIMAB COMBINATIONS AND PROCEDURES |
| CN108218932B (zh) * | 2017-12-27 | 2019-01-04 | 北京大学 | 凝集素受体介导的癌症预靶向治疗药物 |
| US11622976B2 (en) | 2018-01-19 | 2023-04-11 | Delta-Fly Pharma, Inc. | Urine alkali agent useful for treatment of cancer patient |
| US20190358201A1 (en) * | 2018-05-25 | 2019-11-28 | Nantcell, Inc. | Modified doxorubicin compositions and methods |
| US12194111B2 (en) | 2018-10-16 | 2025-01-14 | Nant Holdings Ip, Llc | Alpha emitter compositions and methods |
| US12085571B2 (en) | 2019-06-13 | 2024-09-10 | Immunitybio, Inc. | Biological deposit labeling and tracking including isotope, rare earth metal or mitochondria tags |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8426672D0 (en) | 1984-10-22 | 1984-11-28 | Erba Farmitalia | Pharmaceutical compositions |
| US5977082A (en) | 1985-08-02 | 1999-11-02 | Pharmacia & Upjohn Company | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
| DE69737510T2 (de) | 1996-12-30 | 2007-12-06 | Battelle Memorial Institute, Columbus | Verwendung eines unverkapselten Antikrebs-Arzneimittels zur Herstellung einer Zubereitung zur Behandlung von Neoplasmen durch Inhalation |
| DE19926154A1 (de) | 1999-06-09 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung |
| DE10012120A1 (de) | 2000-03-13 | 2001-09-27 | Ktb Tumorforschungs Gmbh | Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel |
| US20050148534A1 (en) | 2003-09-22 | 2005-07-07 | Castellino Angelo J. | Small molecule compositions and methods for increasing drug efficiency using compositions thereof |
| CA2546237A1 (en) * | 2003-11-18 | 2005-06-02 | Attenuon Llc | Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof |
| GB0621973D0 (en) | 2006-11-03 | 2006-12-13 | Philogen Spa | Binding molecules and uses thereof |
| NZ580866A (en) * | 2007-04-10 | 2011-02-25 | Myriad Pharmaceuticals Inc | Method of treating brain cancer |
| KR20100029764A (ko) | 2007-05-16 | 2010-03-17 | 케이티비 투머포슝스케쉘샤프트 엠비에이치 | 저점성 안트라사이클린 제제 |
| JP5705118B2 (ja) * | 2008-10-15 | 2015-04-22 | アンジオケム インコーポレーテッド | 薬物送達のためのエトポシドおよびドキソルビシン複合体 |
| CN101897667B (zh) * | 2009-05-26 | 2012-01-25 | 石药集团中奇制药技术（石家庄）有限公司 | 一种盐酸多柔比星脂质体注射剂及其制备工艺 |
| EP2382993A1 (en) | 2010-04-19 | 2011-11-02 | KTB Tumorforschungsgesellschaft mbH | Combination of drugs with protein-binding prodrugs |
| EP3915369A1 (en) | 2012-12-13 | 2021-12-01 | CytRx Corporation | Anthracycline formulations |
| AU2014274940B2 (en) | 2013-06-05 | 2019-05-23 | Cytrx Corporation | Cytotoxic agents for the treatment of cancer |
-
2014
- 2014-06-04 AU AU2014274940A patent/AU2014274940B2/en active Active
- 2014-06-04 CN CN201480032023.9A patent/CN105307724A/zh active Pending
- 2014-06-04 BR BR112015030623A patent/BR112015030623A2/pt not_active IP Right Cessation
- 2014-06-04 WO PCT/US2014/040872 patent/WO2014197569A1/en not_active Ceased
- 2014-06-04 KR KR1020157036829A patent/KR102257647B1/ko active Active
- 2014-06-04 KR KR1020237015736A patent/KR20230070328A/ko not_active Ceased
- 2014-06-04 US US14/893,821 patent/US10278981B2/en active Active
- 2014-06-04 KR KR1020217014703A patent/KR20210059035A/ko not_active Ceased
- 2014-06-04 CA CA2912908A patent/CA2912908C/en active Active
- 2014-06-04 CN CN202111190632.5A patent/CN113842392A/zh active Pending
- 2014-06-04 EP EP14807006.3A patent/EP3003489B1/en active Active
- 2014-06-04 JP JP2016517955A patent/JP2016521705A/ja active Pending
- 2014-06-04 NZ NZ631022A patent/NZ631022A/en unknown
- 2014-06-05 TW TW103119626A patent/TW201446251A/zh unknown
- 2014-06-05 AR ARP140102188A patent/AR096526A1/es unknown
-
2019
- 2019-02-19 US US16/279,737 patent/US10881678B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN105307724A (zh) | 2016-02-03 |
| AU2014274940B2 (en) | 2019-05-23 |
| NZ631022A (en) | 2018-05-25 |
| KR102257647B1 (ko) | 2021-05-31 |
| WO2014197569A1 (en) | 2014-12-11 |
| US20160089388A1 (en) | 2016-03-31 |
| EP3003489B1 (en) | 2021-08-18 |
| US10278981B2 (en) | 2019-05-07 |
| TW201446251A (zh) | 2014-12-16 |
| BR112015030623A2 (pt) | 2017-07-25 |
| KR20230070328A (ko) | 2023-05-22 |
| KR20210059035A (ko) | 2021-05-24 |
| CA2912908A1 (en) | 2014-11-12 |
| JP2016521705A (ja) | 2016-07-25 |
| KR20160015289A (ko) | 2016-02-12 |
| US20190350952A1 (en) | 2019-11-21 |
| EP3003489A4 (en) | 2017-02-08 |
| EP3003489A1 (en) | 2016-04-13 |
| CN113842392A (zh) | 2021-12-28 |
| CA2912908C (en) | 2021-06-08 |
| US10881678B2 (en) | 2021-01-05 |
| AU2014274940A1 (en) | 2015-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR096526A1 (es) | Agentes citotóxicos para el tratamiento del cáncer | |
| US9801949B2 (en) | Combinations of albumin-based drug delivery systems | |
| CA2796969C (en) | Combination of drugs with protein-binding prodrugs | |
| AR110301A1 (es) | Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip | |
| AR066544A1 (es) | Metodos de utilizacion de antagonistas de la vasopresina con agentes para quimioterapia con antracina para reducir la cardiotoxicidad y/o aumentar la supervivencia. composicion farmaceutica. | |
| AR051099A1 (es) | Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas | |
| CL2008003153A1 (es) | Compuestos espiro condensados, agonistas de gpr40: composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en la preparacion de medicamentos para el tratamiento de la diabetes, hiperglicemia, alteracion de tolerancia a la glucosa en ayuna, entre otras. | |
| AR059982A1 (es) | Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano | |
| AR078224A1 (es) | Composicon para el tratamiento del cancer de prostata | |
| BR112014015274A8 (pt) | compostos e composições para inibição da interação de bcl2 com parceiros de ligação | |
| BR112021025394A2 (pt) | Derivados de antraciclina, conjugados de fármaco e molécula de ligação ao alvo, uso de conjugado de fármaco e molécula de ligação ao alvo, método de tratamento de uma doença em um paciente em necessidade de tratamento, e composição farmacêutica | |
| CU20090007A6 (es) | Un compuesto farmacéutico y un proceso del mismo | |
| AR127245A1 (es) | Compuestos, composiciones farmacéuticas y métodos para el tratamiento, prevención o manejo de trastornos hiperproliferativos | |
| CO2025002048A2 (es) | Anticuerpos anti monometil auristatina y fragmentos de anticuerpos | |
| MX391965B (es) | Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer. | |
| JPH04500209A (ja) | トポイソメラーゼ阻害剤または細胞分化誘導剤としての五環式トリテルペノイド化合物 | |
| AR074246A1 (es) | Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno | |
| AR129578A1 (es) | MODULADORES DE LA ACTIVIDAD DE TNF-a | |
| AR127243A1 (es) | Compuestos, composiciones farmacéuticas y métodos para el tratamiento, prevención o manejo de trastornos hiperproliferativos | |
| BR112019000049A2 (pt) | terapias combinadas para o tratamento do câncer | |
| BR112023026735A2 (pt) | Conjugado, composto de conector-fármaco, uso de um composto de conector-fármaco, e, composição farmacêutica | |
| AR128539A1 (es) | Terapias combinadas para el tratamiento de cánceres con moléculas de unión terapéuticas | |
| AR130904A1 (es) | Conjugado de anticuerpo-fármaco que contiene un compuesto agonista dual del receptor tipo toll 7/8 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |